{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.5","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"75.8","upperLimit":"97.1","value":"89.7"},{"groupId":"OG002","lowerLimit":"34.9","upperLimit":"96.8","value":"75.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"MRD negativity rate was defined as percentage of participants who had negative MRD by bone marrow aspirate at any timepoint after initial dose of JNJ-68284528 and before disease progression or starting subsequent therapy or retreatment with JNJ-68284528. MRD negativity rate was assessed by next-generation sequencing at a threshold of \\<10\\^5.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"NUMBER","populationDescription":"mITT analysis set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants with evaluable samples for MRD.","reportingStatus":"POSTED","timeFrame":"Pre dose (Day 1) up to 45.2 months","title":"Phase 1b and Phase 2: Minimal Residual Disease (MRD) Negative Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}